nach oben

Applied Health Economics and Health Policy

Erschienen in:

01.06.2014 | Systematic Review

A Systematic Review of Osteoporosis Medication Adherence and Osteoporosis-Related Fracture Costs in Men

verfasst von: Yeshi Mikyas, Irene Agodoa, Nicole Yurgin

Erschienen in: Applied Health Economics and Health Policy | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Background and objective

Male osteoporosis is an increasingly important public health concern. Although several medications are approved for the treatment of osteoporosis, medication non-adherence and the associated consequences are not well documented in male populations. Our objective was to identify and summarize the current knowledge related to osteoporotic medication adherence, the potential implications of non-adherence to the medication, and the cost of osteoporosis-related fractures and health-resource utilization in men.

Methods

Two separate systematic searches were conducted concurrently: one to identify literature reporting male-specific adherence to anti-osteoporotic medication and the clinical consequence of non-adherence in men, and the other to identify literature reporting the cost and resource burden of osteoporosis-related fractures in men. The PubMed, MEDLINE, EMBASE, and Cochrane databases were searched using a date range of 1 January 1998 to 30 June 2012, and citations were screened based on pre-defined criteria.

Results

The percentage of males adherent to bisphosphonates [medication possession ratio (MPR) >0.8] over a 1-year period ranged from 32 % to 64 %. The data imply worse clinical outcomes with treatment non-adherence. Costs and resource use associated with osteoporosis-related fractures in men are high, with hip fractures generating the most cost.

Conclusions

One-third to two-thirds of men are not adherent to bisphosphonates. Non-adherence is associated with increased fracture risk. Estimates of direct and indirect osteoporosis-related fracture costs are also substantial in men, and may even be more costly than in women. More robust data would better inform disease management initiatives that could improve adherence to medication and outcomes in men with osteoporosis.

Nur mit Berechtigung zugänglich

WHO Technical Report Series 921. Report of a WHO Scientific Group (2003). Prevention and management of osteoporosis. http://whqlibdoc.who.int/trs/who_trs_921.pdf. Accessed 9 Nov 2012.

Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007;22(3):465–75.PubMedCrossRef

Boonen S, Laan RF, Barton IP, Watts NB. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int. 2005;16(10):1291–8.PubMedCrossRef

Strom O, Borgstrom F, Kanis JA, Compston J, Cooper C, McCloskey EV, et al. Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2011;6(1–2):59–155.PubMedCrossRef

Endo Y, Aharonoff GB, Zuckerman JD, Egol KA, Koval KJ. Gender differences in patients with hip fracture: a greater risk of morbidity and mortality in men. J Orthop Trauma. 2005;19(1):29–35.PubMedCrossRef

Hawkes WG, Wehren L, Orwig D, Hebel JR, Magaziner J. Gender differences in functioning after hip fracture. J Gerontol A Biol Sci Med Sci. 2006;61(5):495–9.PubMedCrossRef

Kannegaard PN, van der Mark S, Eiken P, Abrahamsen B. Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival. Age Ageing. 2010;39(2):203–9.PubMedCrossRef

Kiebzak GM, Beinart GA, Perser K, Ambrose CG, Siff SJ, Heggeness MH. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med. 2002;162(19):2217–22.PubMedCrossRef

Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343(9):604–10.PubMedCrossRef

10.

Reid DM, Adami S, Devogelaer JP, Chines AA. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif Tissue Int. 2001;69(4):242–7.PubMedCrossRef

11.

Sato Y, Iwamoto J, Kanoko T, Satoh K. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med. 2005;165(15):1743–8.PubMedCrossRef

12.

Orwoll E, Teglbjaerg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL, et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab. 2012;97(9):3161–9.PubMedCrossRef

13.

Lekkerkerker F, Kanis JA, Alsayed N, Bouvenot G, Burlet N, Cahall D, et al. Adherence to treatment of osteoporosis: a need for study. Osteoporos Int. 2007;18(10):1311–7.PubMedCrossRef

14.

Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007;82(12):1493–501.PubMedCrossRef

15.

Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007;18(8):1023–31.PubMedCrossRef

16.

The World Bank. Inflation, consumer prices (annual %). http://data.worldbank.org/indicator/FP.CPI.TOTL.ZG. Accessed 11 Sep 2013.

17.

The World Bank. PPP conversion factor, GDP (LCU per international $). http://data.worldbank.org/indicator/PA.NUS.PPP/countries?page=1&display=default. Accessed 11 Sep 2013.

18.

Abhishek A, Pande I. Teriparatide in men: persistence and geographical variation in the UK. Osteoporos Int. 2009;20(8):1453–4.PubMedCrossRef

19.

Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008;28(4):437–43.PubMedCrossRefPubMedCentral

20.

Briesacher BA, Andrade SE, Harrold LR, Fouayzi H, Yood RA. Adoption of once-monthly oral bisphosphonates and the impact on adherence. Am J Med. 2010;123(3):275–80.PubMedCrossRefPubMedCentral

21.

Cevikoi A, Umay E, Polat S, Ecerkale O, Cakci A. The relationship between bisphosphonate use and demographic characteristics of male osteoporosis patients. Clinics (Sao Paulo). 2011;66(4):579–82.CrossRef

22.

Curtis JR, Westfall AO, Cheng H, Lyles K, Saag KG, Delzell E. Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res. 2008;23(9):1435–41.PubMedCrossRefPubMedCentral

23.

Devold HM, Furu K, Skurtveit S, Tverdal A, Falch JA, Sogaard AJ. Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway. Pharmacoepidemiol Drug Saf. 2012;21(3):297–304.PubMedCrossRef

24.

Gallagher AM, Rietbrock S, Olson M, van Staa TP. Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res. 2008;23(10):1569–75.PubMedCrossRef

25.

Hansen KE, Swenson ED, Baltz B, Schuna AA, Jones AN, Elliott ME. Adherence to alendronate in male veterans. Osteoporos Int. 2008;19(3):349–56.PubMedCrossRef

26.

Kamatari M, Koto S, Ozawa N, Urao C, Suzuki Y, Akasaka E, et al. Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab. 2007;25(5):302–9.PubMedCrossRef

27.

Kuo I, Ong C, Simmons L, Bliuc D, Eisman J, Center J. Successful direct intervention for osteoporosis in patients with minimal trauma fractures. Osteoporos Int. 2007;18(12):1633–9.PubMedCrossRef

28.

Lin TC, Yang CY, Yang YH, Lin SJ. Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan. Clin Pharmacol Ther. 2011;90(1):109–16.PubMedCrossRef

29.

Netelenbos JC, Geusens PP, Ypma G, Buijs SJ. Adherence and profile of non-persistence in patients treated for osteoporosis: a large-scale, long-term retrospective study in The Netherlands. Osteoporos Int. 2011;22(5):1537–46.PubMedCrossRefPubMedCentral

30.

Rietbrock S, Olson M, van Staa TP. The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates. QJM. 2009;102(1):35–42.PubMedCrossRef

31.

Ringe JD, Dorst A, Farahmand P. Comparing once yearly zoledronic acid with once weekly generic alendronate in the treatment of established male osteoporosis [abstract no. P840]. Osteoporos Int. 2010;21(Suppl 1):S357.

32.

Roerholt C, Eiken P, Abrahamsen B. Initiation of anti-osteoporotic therapy in patients with recent fractures: a nationwide analysis of prescription rates and persistence. Osteoporos Int. 2009;20(2):299–307.PubMedCrossRef

33.

Vytrisalova M, Blazkova S. Exposure to osteoporosis medication in men [abstract no. PMS92]. Value Health. 2009;12(7):A450–51.

34.

Wade SW, Curtis JR, Yu J, White J, Stolshek BS, Merinar C, et al. Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan. Bone. 2012;50(4):870–5.PubMedCrossRef

35.

Sheehy O, Kindundu CM, Barbeau M, LeLorier J. Differences in persistence among different weekly oral bisphosphonate medications. Osteoporos Int. 2009;20(8):1369–76.PubMedCrossRef

36.

Borgstrom F, Sobocki P, Strom O, Jonsson B. The societal burden of osteoporosis in Sweden. Bone. 2007;40(6):1602–9.PubMedCrossRef

37.

Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, et al. Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int. 2006;17(5):637–50.PubMedCrossRef

38.

Konnopka A, Jerusel N, Konig HH. The health and economic consequences of osteopenia- and osteoporosis-attributable hip fractures in Germany: estimation for 2002 and projection until 2050. Osteoporos Int. 2009;20(7):1117–29.PubMedCrossRef

39.

Max W, Sinnot P, Kao C, Sung HY, Rice DP. The burden of osteoporosis in California, 1998. Osteoporos Int. 2002;13(6):493–500.PubMedCrossRef

40.

Rabenda V, Manette C, Lemmens R, Mariani AM, Struvay N, Reginster JY. The direct and indirect costs of the chronic management of osteoporosis: a prospective follow-up of 3440 active subjects. Osteoporos Int. 2006;17(9):1346–52.PubMedCrossRef

41.

Bass E, French DD, Bradham DD. A national perspective of Medicare expenditures for elderly veterans with hip fractures. J Am Med Dir Assoc. 2008;9(2):114–9.PubMedCrossRef

42.

Blume SW, Curtis JR. Medical costs of osteoporosis in the elderly Medicare population. Osteoporos Int. 2011;22(6):1835–44.PubMedCrossRefPubMedCentral

43.

Burge RT, King AB, Balda E, Worley D. Methodology for estimating current and future burden of osteoporosis in state populations: application to Florida in 2000 through 2025. Value Health. 2003;6(5):574–83.PubMedCrossRef

44.

Christensen L, Iqbal S, Macarios D, Badamgarav E, Harley C. Cost of fractures commonly associated with osteoporosis in a managed-care population. J Med Econ. 2010;13(2):302–13.PubMedCrossRef

45.

Haussler B, Gothe H, Gol D, Glaeske G, Pientka L, Felsenberg D. Epidemiology, treatment and costs of osteoporosis in Germany–the BoneEVA Study. Osteoporos Int. 2007;18(1):77–84.PubMedCrossRef

46.

King AB, Tosteson AN, Wong JB, Solomon DH, Burge RT, Dawson-Hughes B. Interstate variation in the burden of fragility fractures. J Bone Miner Res. 2009;24(4):681–92.PubMedCrossRefPubMedCentral

47.

Leslie WD, Metge CJ, Azimaee M, Lix LM, Finlayson GS, Morin SN, et al. Direct costs of fractures in Canada and trends 1996–2006: a population-based cost-of-illness analysis. J Bone Miner Res. 2011;26(10):2419–29.PubMedCrossRef

48.

Levy P, Levy E, Audran M, Cohen-Solal M, Fardellone P, Le Parc JM. The cost of osteoporosis in men: the French situation. Bone. 2002;30(4):631–6.PubMedCrossRef

49.

Melton LJ 3rd, Gabriel SE, Crowson CS, Tosteson AN, Johnell O, Kanis JA. Cost-equivalence of different osteoporotic fractures. Osteoporos Int. 2003;14(5):383–8.PubMedCrossRef

50.

Ohsfeldt RL, Borisov NN, Sheer RL. Fragility fracture-related direct medical costs in the first year following a nonvertebral fracture in a managed care setting. Osteoporos Int. 2006;17(2):252–8.PubMedCrossRef

51.

Pfister AK, Sale WG, Shaukat S. The economics of fragility fractures in West Virginia. W V Med J. 2009;105(4):10–3.PubMed

52.

Strom O, Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, et al. Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop. 2008;79(2):269–80.PubMedCrossRef

53.

Bouza C, Lopez T, Palma M, Amate JM. Hospitalised osteoporotic vertebral fractures in Spain: analysis of the national hospital discharge registry. Osteoporos Int. 2007;18(5):649–57.PubMedCrossRef

54.

Bubshait D, Sadat-Ali M. Economic implications of osteoporosis-related femoral fractures in Saudi Arabian society. Calcif Tissue Int. 2007;81(6):455–8.PubMedCrossRef

55.

Dai K, Zhang Q, Fan T, Sen SS. Estimation of resource utilization associated with osteoporotic hip fracture and level of post-acute care in China. Curr Med Res Opin. 2007;23(12):2937–43.PubMedCrossRef

56.

Finnern HW, Sykes DP. The hospital cost of vertebral fractures in the EU: estimates using national datasets. Osteoporos Int. 2003;14(5):429–36.PubMedCrossRef

57.

Ganesan K, Pan D, Teklehaimenot S, Norris K. Racial differences in institutionalization after hip fractures: California hospital discharge data. Ethn Dis. 2005;15(4 Suppl 5):S5-30-3.

58.

Gehlbach SH, Avrunin JS, Puleo E. Trends in hospital care for hip fractures. Osteoporos Int. 2007;18(5):585–91.PubMedCrossRef

59.

Gehlbach SH, Burge RT, Puleo E, Klar J. Hospital care of osteoporosis-related vertebral fractures. Osteoporos Int. 2003;14(1):53–60.PubMedCrossRef

60.

Hepguler S, Cetin A, Deger C, Erkent U. Osteoporotic hip fracture costs in the elderly Turkish population. Acta Orthop Traumatol Turc. 2011;45(5):316–25.PubMed

61.

Koeck CM, Schwappach DL, Niemann FM, Strassmann TJ, Ebner H, Klaushofer K. Incidence and costs of osteoporosis-associated hip fractures in Austria. Wien Klin Wochenschr. 2001;113(10):371–7.PubMed

62.

Lee YH, Lim YW, Lam KS. Economic cost of osteoporotic hip fractures in Singapore. Singapore Med J. 2008;49(12):980–4.PubMed

63.

Lippuner K, Golder M, Greiner R. Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. Osteoporos Int. 2005;16(Suppl 2):S8–17.PubMedCrossRef

64.

Lippuner K, Grifone S, Schwenkglenks M, Schwab P, Popp AW, Senn C, et al. Comparative trends in hospitalizations for osteoporotic fractures and other frequent diseases between 2000 and 2008. Osteoporos Int. 2012;23(3):829–39.PubMedCrossRef

65.

Lonnroos E, Kautiainen H, Sund R, Karppi P, Hartikainen S, Kiviranta I, et al. Utilization of inpatient care before and after hip fracture: a population-based study. Osteoporos Int. 2009;20(6):879–86.PubMedCrossRef

66.

Lubbeke A, Stern R, Grab B, Herrmann F, Michel JP, Hoffmeyer P. Upper extremity fractures in the elderly: consequences on utilization of rehabilitation care. Aging Clin Exp Res. 2005;17(4):276–80.PubMedCrossRef

67.

Reginster JY, Gillet P, Ben Sedrine W, Brands G, Ethgen O, de Froidmont C, et al. Direct costs of hip fractures in patients over 60 years of age in Belgium. Pharmacoeconomics. 1999;15(5):507–14.PubMedCrossRef

68.

Russo A, Holmquist L, Elixhauser A. U.S. hospitalizations involving osteoporosis and injury, 2006. Health Cost Utilization Project Statistical Brief #76. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb76.jsp.

69.

Wiktorowicz ME, Goeree R, Papaioannou A, Adachi JD, Papadimitropoulos E. Economic implications of hip fracture: health service use, institutional care and cost in Canada. Osteoporos Int. 2001;12(4):271–8.PubMedCrossRef

70.

Song X, Shi N, Badamgarav E, Kallich J, Varker H, Lenhart G, et al. Cost burden of second fracture in the US health system. Bone. 2011;48(4):828–36.PubMedCrossRef

71.

Johnell O, Kanis JA, Jonsson B, Oden A, Johansson H, De Laet C. The burden of hospitalised fractures in Sweden. Osteoporos Int. 2005;16(2):222–8.PubMedCrossRef

72.

Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81(8):1013–22.PubMedCrossRef

73.

Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int. 2010;21(11):1943–51.PubMedCrossRef

74.

Lo JC, Pressman AR, Omar MA, Ettinger B. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int. 2006;17(6):922–8.PubMedCrossRef

75.

Dell R, Greene D, Schelkun SR, Williams K. Osteoporosis disease management: the role of the orthopaedic surgeon. J Bone Joint Surgery Am. 2008;90(Suppl 4):188–94.CrossRef

76.

Harrington JT, Lease J. Osteoporosis disease management for fragility fracture patients: new understandings based on three years’ experience with an osteoporosis care service. Arthritis Rheum. 2007;57(8):1502–6.PubMedCrossRef

77.

McLellan AR, Wolowacz SE, Zimovetz EA, Beard SM, Lock S, McCrink L, et al. Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int. 2011;22(7):2083–98.PubMedCrossRef

78.

Newman ED, Ayoub WT, Starkey RH, Diehl JM, Wood GC. Osteoporosis disease management in a rural health care population: hip fracture reduction and reduced costs in postmenopausal women after 5 years. Osteoporos Int. 2003;14(2):146–51.PubMed

Titel: A Systematic Review of Osteoporosis Medication Adherence and Osteoporosis-Related Fracture Costs in Men
verfasst von: Yeshi Mikyas
Irene Agodoa
Nicole Yurgin
Publikationsdatum: 01.06.2014
Verlag: Springer International Publishing
Erschienen in: Applied Health Economics and Health Policy / Ausgabe 3/2014
Print ISSN: 1175-5652
Elektronische ISSN: 1179-1896
DOI: https://doi.org/10.1007/s40258-013-0078-1

Springer Medizin

Abstract

Background and objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2014

Assessing Medication Adherence and Healthcare Utilization and Cost Patterns Among Hospital-Discharged Patients with Schizoaffective Disorder

Modelling the Economics of Type 2 Diabetes Mellitus Prevention: A Literature Review of Methods

Healthcare Use and Voluntary Health Insurance After Retirement in Thailand

Biosimilar Granulocyte Colony-Stimulating Factor Uptakes in the EU-5 Markets: A Descriptive Analysis

Paying for Formerly Free Medicines in Spain After 1 Year of Co-Payment: Changes in the Number of Dispensed Prescriptions

Current Status and Trends in Performance-Based Risk-Sharing Arrangements Between Healthcare Payers and Medical Product Manufacturers